FDA Awards New Five-Year $7.9M Contract to ACMT to Expand Drug Surveillance Activities

We are thrilled to announce that the Food and Drug Administration (FDA) has awarded ACMT a new 5-year $7.9 million contract to expand ACMT’s Toxicology Investigators Consortium (ToxIC) drug surveillance activities.

In 2020, with FDA funding, ToxIC stood-up a 15 site surveillance network that initially focused on identifying and reporting on adverse events related to the treatment and/or prophylaxis of patients with COVID-19. In 2021 this program was expanded to 17 sites and in recent months began to also report on cases of opioid and/or stimulant use related to COVID-19. With this new contract we will be adding a laboratory/analytical component to our work as part of an enhanced surveillance program.

The ACMT Board of Directors is especially grateful to the Principal Investigators Paul Wax, MD, FACMT and Jeffrey Brent, MD, PhD, FACMT, and ToxIC Program Director Kim Aldy, DO, MBA for leading the development of the new proposal. We are indebted to all the ACMT members at ToxIC sites for their support and 12 years of hard work which has established a track record that made ACMT competitive to receive this award.